Zura Bio (NASDAQ:ZURA) Sees Large Volume Increase - Here's Why

Key Points

• Zura Bio shares traded around $6.41 after approximately 703,847 shares changed hands, although volume was 20% lower than in the prior session.
• Analyst sentiment remains favorable, with Wedbush and Guggenheim raising their price targets to $22 and $20, respectively. The stock has a consensus “Moderate Buy” rating and a $17 target price.
• Institutional investors own 61.14% of Zura Bio, with several hedge funds increasing their positions. The clinical-stage biotechnology company reported a quarterly loss of $0.21 per share and is expected to post a full-year loss of $0.81 per share.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) shares saw an uptick in trading volume on Tuesday . Approximately 703,847 shares changed hands during mid-day trading, a decline of 20% from the previous session's volume of 877,647 shares.The stock last traded at $6.4050 and had previously closed at $6.30.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZURA. Wedbush increased their target price on shares of Zura Bio from $15.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, August 12th. Guggenheim upped their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded Zura Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. William Blair initiated coverage on Zura Bio in a report on Wednesday, July 8th. They issued an "outperform" rating for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Zura Bio in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zura Bio has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

Zura Bio Stock Performance

The firm has a market capitalization of $618.58 million, a price-to-earnings ratio of -5.74 and a beta of -0.02. The firm has a fifty day moving average price of $5.26 and a 200 day moving average price of $5.39.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.21) EPS for the quarter. Research analysts predict that Zura Bio Limited will post -0.81 earnings per share for the current fiscal year.

Institutional Trading of Zura Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Montanova Capital LLC increased its stake in Zura Bio by 4.1% in the second quarter. Montanova Capital LLC now owns 9,443,001 shares of the company's stock valued at $55,714,000 after purchasing an additional 376,000 shares during the last quarter. Suvretta Capital Management LLC boosted its stake in Zura Bio by 1.7% in the 4th quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company's stock worth $29,171,000 after buying an additional 94,110 shares during the last quarter. VR Adviser LLC boosted its stake in Zura Bio by 15.4% in the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company's stock worth $28,008,000 after buying an additional 713,899 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company's stock valued at $4,893,000 after buying an additional 2,052,732 shares during the period. Finally, Siren L.L.C. grew its holdings in Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company's stock valued at $22,222,000 after buying an additional 2,434,866 shares during the period. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source